JP4891250B2 - 脱アミドされたインターフェロンβ - Google Patents
脱アミドされたインターフェロンβ Download PDFInfo
- Publication number
- JP4891250B2 JP4891250B2 JP2007540208A JP2007540208A JP4891250B2 JP 4891250 B2 JP4891250 B2 JP 4891250B2 JP 2007540208 A JP2007540208 A JP 2007540208A JP 2007540208 A JP2007540208 A JP 2007540208A JP 4891250 B2 JP4891250 B2 JP 4891250B2
- Authority
- JP
- Japan
- Prior art keywords
- ifn
- composition
- deamidated
- protein
- protein analog
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 108090000467 Interferon-beta Proteins 0.000 title claims abstract description 158
- 102000003996 Interferon-beta Human genes 0.000 title claims abstract description 20
- 229960001388 interferon-beta Drugs 0.000 title claims abstract description 17
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 69
- 235000018102 proteins Nutrition 0.000 claims abstract description 68
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 68
- 238000000034 method Methods 0.000 claims abstract description 34
- 230000004071 biological effect Effects 0.000 claims abstract description 31
- 201000006417 multiple sclerosis Diseases 0.000 claims abstract description 18
- 238000011282 treatment Methods 0.000 claims abstract description 15
- 101001054334 Homo sapiens Interferon beta Proteins 0.000 claims abstract description 10
- 238000004519 manufacturing process Methods 0.000 claims abstract description 10
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 claims abstract description 9
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims abstract description 8
- 229960001230 asparagine Drugs 0.000 claims abstract description 8
- 235000009582 asparagine Nutrition 0.000 claims abstract description 8
- 201000010099 disease Diseases 0.000 claims abstract description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 6
- 102100026720 Interferon beta Human genes 0.000 claims description 138
- 239000000203 mixture Substances 0.000 claims description 38
- -1 cyclic imide Chemical class 0.000 claims description 35
- 230000000694 effects Effects 0.000 claims description 18
- 150000001413 amino acids Chemical class 0.000 claims description 11
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims description 9
- 229940009098 aspartate Drugs 0.000 claims description 8
- 230000007935 neutral effect Effects 0.000 claims description 8
- 238000011534 incubation Methods 0.000 claims description 7
- 229940024606 amino acid Drugs 0.000 claims description 6
- 235000001014 amino acid Nutrition 0.000 claims description 6
- 230000001225 therapeutic effect Effects 0.000 claims description 6
- 235000018417 cysteine Nutrition 0.000 claims description 5
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 5
- 230000003612 virological effect Effects 0.000 claims description 5
- 229930182817 methionine Natural products 0.000 claims description 4
- 230000010261 cell growth Effects 0.000 claims description 3
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 claims description 3
- 210000000822 natural killer cell Anatomy 0.000 claims description 3
- 230000006269 (delayed) early viral mRNA transcription Effects 0.000 claims description 2
- 102000014150 Interferons Human genes 0.000 claims description 2
- 108010050904 Interferons Proteins 0.000 claims description 2
- 108091006028 deamidated proteins Proteins 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 229940079322 interferon Drugs 0.000 claims description 2
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 claims description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-L aspartate group Chemical group N[C@@H](CC(=O)[O-])C(=O)[O-] CKLJMWTZIZZHCS-REOHCLBHSA-L 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 230000004936 stimulating effect Effects 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract description 22
- 238000004007 reversed phase HPLC Methods 0.000 abstract description 19
- 239000003814 drug Substances 0.000 abstract description 15
- 238000003908 quality control method Methods 0.000 abstract description 5
- 230000029983 protein stabilization Effects 0.000 abstract description 3
- 230000002255 enzymatic effect Effects 0.000 abstract 1
- 238000010348 incorporation Methods 0.000 abstract 1
- 238000012113 quantitative test Methods 0.000 abstract 1
- 230000006240 deamidation Effects 0.000 description 37
- 239000000523 sample Substances 0.000 description 33
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 21
- 230000000120 cytopathologic effect Effects 0.000 description 18
- 210000004027 cell Anatomy 0.000 description 14
- 238000009472 formulation Methods 0.000 description 13
- 229940088679 drug related substance Drugs 0.000 description 12
- PZBFGYYEXUXCOF-UHFFFAOYSA-N TCEP Chemical group OC(=O)CCP(CCC(O)=O)CCC(O)=O PZBFGYYEXUXCOF-UHFFFAOYSA-N 0.000 description 11
- 239000008186 active pharmaceutical agent Substances 0.000 description 11
- 229940126534 drug product Drugs 0.000 description 10
- 239000000825 pharmaceutical preparation Substances 0.000 description 10
- 230000001028 anti-proliverative effect Effects 0.000 description 8
- 230000002829 reductive effect Effects 0.000 description 8
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 230000029087 digestion Effects 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 239000012634 fragment Substances 0.000 description 6
- 229940124597 therapeutic agent Drugs 0.000 description 6
- 238000003556 assay Methods 0.000 description 5
- 238000004166 bioassay Methods 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 4
- 108020004511 Recombinant DNA Proteins 0.000 description 4
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 235000003704 aspartic acid Nutrition 0.000 description 4
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000003638 chemical reducing agent Substances 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 231100000673 dose–response relationship Toxicity 0.000 description 4
- 239000012149 elution buffer Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000012544 monitoring process Methods 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 108010005714 Interferon beta-1b Proteins 0.000 description 3
- 108010033276 Peptide Fragments Proteins 0.000 description 3
- 102000007079 Peptide Fragments Human genes 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 239000013068 control sample Substances 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000006862 enzymatic digestion Effects 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 229960003161 interferon beta-1b Drugs 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 238000002703 mutagenesis Methods 0.000 description 3
- 231100000350 mutagenesis Toxicity 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 238000012510 peptide mapping method Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- 101001018085 Lysobacter enzymogenes Lysyl endopeptidase Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 239000001099 ammonium carbonate Substances 0.000 description 2
- 229940021459 betaseron Drugs 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000005341 cation exchange Methods 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 238000007385 chemical modification Methods 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012537 formulation buffer Substances 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 238000011031 large-scale manufacturing process Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000004811 liquid chromatography Methods 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000013207 serial dilution Methods 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- CWERGRDVMFNCDR-UHFFFAOYSA-N thioglycolic acid Chemical compound OC(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-N 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- QZTKDVCDBIDYMD-UHFFFAOYSA-N 2,2'-[(2-amino-2-oxoethyl)imino]diacetic acid Chemical compound NC(=O)CN(CC(O)=O)CC(O)=O QZTKDVCDBIDYMD-UHFFFAOYSA-N 0.000 description 1
- IHPYMWDTONKSCO-UHFFFAOYSA-N 2,2'-piperazine-1,4-diylbisethanesulfonic acid Chemical compound OS(=O)(=O)CCN1CCN(CCS(O)(=O)=O)CC1 IHPYMWDTONKSCO-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- AJTVSSFTXWNIRG-UHFFFAOYSA-N 2-[bis(2-hydroxyethyl)amino]ethanesulfonic acid Chemical compound OCC[NH+](CCO)CCS([O-])(=O)=O AJTVSSFTXWNIRG-UHFFFAOYSA-N 0.000 description 1
- LVQFQZZGTZFUNF-UHFFFAOYSA-N 2-hydroxy-3-[4-(2-hydroxy-3-sulfonatopropyl)piperazine-1,4-diium-1-yl]propane-1-sulfonate Chemical compound OS(=O)(=O)CC(O)CN1CCN(CC(O)CS(O)(=O)=O)CC1 LVQFQZZGTZFUNF-UHFFFAOYSA-N 0.000 description 1
- DVLFYONBTKHTER-UHFFFAOYSA-N 3-(N-morpholino)propanesulfonic acid Chemical compound OS(=O)(=O)CCCN1CCOCC1 DVLFYONBTKHTER-UHFFFAOYSA-N 0.000 description 1
- NUFBIAUZAMHTSP-UHFFFAOYSA-N 3-(n-morpholino)-2-hydroxypropanesulfonic acid Chemical compound OS(=O)(=O)CC(O)CN1CCOCC1 NUFBIAUZAMHTSP-UHFFFAOYSA-N 0.000 description 1
- RZQXOGQSPBYUKH-UHFFFAOYSA-N 3-[[1,3-dihydroxy-2-(hydroxymethyl)propan-2-yl]azaniumyl]-2-hydroxypropane-1-sulfonate Chemical compound OCC(CO)(CO)NCC(O)CS(O)(=O)=O RZQXOGQSPBYUKH-UHFFFAOYSA-N 0.000 description 1
- XCBLFURAFHFFJF-UHFFFAOYSA-N 3-[bis(2-hydroxyethyl)azaniumyl]-2-hydroxypropane-1-sulfonate Chemical compound OCCN(CCO)CC(O)CS(O)(=O)=O XCBLFURAFHFFJF-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 239000007991 ACES buffer Substances 0.000 description 1
- 239000007988 ADA buffer Substances 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 1
- 108700016232 Arg(2)-Sar(4)- dermorphin (1-4) Proteins 0.000 description 1
- KLKHFFMNGWULBN-VKHMYHEASA-N Asn-Gly Chemical class NC(=O)C[C@H](N)C(=O)NCC(O)=O KLKHFFMNGWULBN-VKHMYHEASA-N 0.000 description 1
- 239000007992 BES buffer Substances 0.000 description 1
- 239000007989 BIS-Tris Propane buffer Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 208000011691 Burkitt lymphomas Diseases 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- OWXMKDGYPWMGEB-UHFFFAOYSA-N HEPPS Chemical compound OCCN1CCN(CCCS(O)(=O)=O)CC1 OWXMKDGYPWMGEB-UHFFFAOYSA-N 0.000 description 1
- GIZQLVPDAOBAFN-UHFFFAOYSA-N HEPPSO Chemical compound OCCN1CCN(CC(O)CS(O)(=O)=O)CC1 GIZQLVPDAOBAFN-UHFFFAOYSA-N 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 108010005716 Interferon beta-1a Proteins 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 108010053229 Lysyl endopeptidase Proteins 0.000 description 1
- 239000007987 MES buffer Substances 0.000 description 1
- 239000007993 MOPS buffer Substances 0.000 description 1
- DBXNUXBLKRLWFA-UHFFFAOYSA-N N-(2-acetamido)-2-aminoethanesulfonic acid Chemical compound NC(=O)CNCCS(O)(=O)=O DBXNUXBLKRLWFA-UHFFFAOYSA-N 0.000 description 1
- JOCBASBOOFNAJA-UHFFFAOYSA-N N-tris(hydroxymethyl)methyl-2-aminoethanesulfonic acid Chemical compound OCC(CO)(CO)NCCS(O)(=O)=O JOCBASBOOFNAJA-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 239000007990 PIPES buffer Substances 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 1
- 235000012501 ammonium carbonate Nutrition 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940003504 avonex Drugs 0.000 description 1
- OWMVSZAMULFTJU-UHFFFAOYSA-N bis-tris Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 description 1
- HHKZCCWKTZRCCL-UHFFFAOYSA-N bis-tris propane Chemical compound OCC(CO)(CO)NCCCNC(CO)(CO)CO HHKZCCWKTZRCCL-UHFFFAOYSA-N 0.000 description 1
- 239000010836 blood and blood product Substances 0.000 description 1
- 229940125691 blood product Drugs 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 238000005277 cation exchange chromatography Methods 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 150000003950 cyclic amides Chemical class 0.000 description 1
- UFULAYFCSOUIOV-UHFFFAOYSA-N cysteamine Chemical compound NCCS UFULAYFCSOUIOV-UHFFFAOYSA-N 0.000 description 1
- 238000001739 density measurement Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 229960003151 mercaptamine Drugs 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 210000004126 nerve fiber Anatomy 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000955 prescription drug Substances 0.000 description 1
- 238000011112 process operation Methods 0.000 description 1
- 230000009696 proliferative response Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000004952 protein activity Effects 0.000 description 1
- 229940124272 protein stabilizer Drugs 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003104 tissue culture media Substances 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/565—IFN-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Virology (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US62683704P | 2004-11-10 | 2004-11-10 | |
| US60/626,837 | 2004-11-10 | ||
| PCT/US2005/040758 WO2006053134A2 (en) | 2004-11-10 | 2005-11-10 | Deamidated interferon-beta |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008519769A JP2008519769A (ja) | 2008-06-12 |
| JP2008519769A5 JP2008519769A5 (https=) | 2008-11-13 |
| JP4891250B2 true JP4891250B2 (ja) | 2012-03-07 |
Family
ID=36337216
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007540208A Expired - Fee Related JP4891250B2 (ja) | 2004-11-10 | 2005-11-10 | 脱アミドされたインターフェロンβ |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US7595040B2 (https=) |
| EP (1) | EP1809662B1 (https=) |
| JP (1) | JP4891250B2 (https=) |
| KR (1) | KR101330626B1 (https=) |
| CN (1) | CN101056890B (https=) |
| AT (1) | ATE415421T1 (https=) |
| AU (1) | AU2005304486B2 (https=) |
| BR (1) | BRPI0517697A (https=) |
| CA (1) | CA2587061C (https=) |
| DE (1) | DE602005011321D1 (https=) |
| ES (1) | ES2318575T3 (https=) |
| MX (1) | MX2007004990A (https=) |
| PL (1) | PL1809662T3 (https=) |
| PT (1) | PT1809662E (https=) |
| RU (1) | RU2404190C2 (https=) |
| WO (1) | WO2006053134A2 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030190307A1 (en) | 1996-12-24 | 2003-10-09 | Biogen, Inc. | Stable liquid interferon formulations |
| CN101506232A (zh) * | 2006-08-08 | 2009-08-12 | 诺瓦提斯公司 | 具有增强的生物活性的重组干扰素-β |
| US8114630B2 (en) | 2007-05-02 | 2012-02-14 | Ambrx, Inc. | Modified interferon beta polypeptides and their uses |
| EP2207890A4 (en) * | 2007-10-05 | 2010-12-15 | Barofold Inc | HIGH PRESSURE PROCESSING OF AGGREGATED INTERFERONS |
| CN106132983B (zh) * | 2014-04-04 | 2021-03-26 | 阿雷斯贸易股份有限公司 | 新型IFN-β蛋白类似物 |
| RU2739261C1 (ru) * | 2019-12-31 | 2020-12-22 | Федеральное государственное бюджетное учреждение науки институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова Российской академии наук (ИБХ РАН) | Способ количественного определения антипролиферативной активности интерферона-бета человека |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4588585A (en) | 1982-10-19 | 1986-05-13 | Cetus Corporation | Human recombinant cysteine depleted interferon-β muteins |
| US4737462A (en) | 1982-10-19 | 1988-04-12 | Cetus Corporation | Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β |
| US4959314A (en) | 1984-11-09 | 1990-09-25 | Cetus Corporation | Cysteine-depleted muteins of biologically active proteins |
| GB9111902D0 (en) | 1991-06-03 | 1991-07-24 | Glaxo Group Ltd | Chemical compounds |
| TR199901968T2 (xx) | 1996-12-24 | 1999-12-21 | Biogen, Inc. | Sabit s�v� interferon form�lleri. |
| US20030190307A1 (en) | 1996-12-24 | 2003-10-09 | Biogen, Inc. | Stable liquid interferon formulations |
| US6696423B1 (en) | 1997-08-29 | 2004-02-24 | Biogen, Inc. | Methods and compositions for therapies using genes encoding secreted proteins such as interferon-beta |
| EP1426058A3 (de) * | 1997-09-23 | 2004-07-28 | Dr. Rentschler Biotechnologie GmbH | Flüssige Interferon-Beta Formulierungen |
| ATE488529T1 (de) | 1999-07-28 | 2010-12-15 | Genentech Inc | Zusammensetzungen und verfahren zur behandlung von tumoren |
| ES2180416B1 (es) | 2001-03-12 | 2004-06-01 | BIOTOOLS BIOTECHNOLOGICAL & MEDICAL LABORATORIES, S.A. | Procedimiento para la preparacion de mezclas de reaccion estabilizadas, total o parcialmente desecadas, que comprenden, al menos, una enzima, mezclas de reaccion y kits que las contienen. |
| AR034749A1 (es) * | 2001-07-09 | 2004-03-17 | Schering Ag | Formulaciones de interferon beta humano |
| RU2216345C1 (ru) * | 2002-03-21 | 2003-11-20 | Закрытое Акционерное Общество "Биокад" | Средство, обладающее иммуномодулирующим, противовирусным, противобактериальным, регенерирующим, репаративным, мембрано- и гепатопротекторным действием |
| KR100541850B1 (ko) | 2003-03-31 | 2006-01-11 | 삼성정밀화학 주식회사 | 인간 인터페론-베타 변이체 및 그의 제조방법 |
-
2005
- 2005-11-10 ES ES05818235T patent/ES2318575T3/es not_active Expired - Lifetime
- 2005-11-10 AT AT05818235T patent/ATE415421T1/de active
- 2005-11-10 PL PL05818235T patent/PL1809662T3/pl unknown
- 2005-11-10 MX MX2007004990A patent/MX2007004990A/es active IP Right Grant
- 2005-11-10 KR KR1020077011869A patent/KR101330626B1/ko not_active Expired - Fee Related
- 2005-11-10 JP JP2007540208A patent/JP4891250B2/ja not_active Expired - Fee Related
- 2005-11-10 RU RU2007121515/04A patent/RU2404190C2/ru not_active IP Right Cessation
- 2005-11-10 BR BRPI0517697-2A patent/BRPI0517697A/pt not_active IP Right Cessation
- 2005-11-10 AU AU2005304486A patent/AU2005304486B2/en not_active Ceased
- 2005-11-10 DE DE602005011321T patent/DE602005011321D1/de not_active Expired - Lifetime
- 2005-11-10 CN CN2005800381182A patent/CN101056890B/zh not_active Expired - Fee Related
- 2005-11-10 WO PCT/US2005/040758 patent/WO2006053134A2/en not_active Ceased
- 2005-11-10 EP EP05818235A patent/EP1809662B1/en not_active Expired - Lifetime
- 2005-11-10 PT PT05818235T patent/PT1809662E/pt unknown
- 2005-11-10 US US11/271,516 patent/US7595040B2/en not_active Expired - Fee Related
- 2005-11-10 CA CA2587061A patent/CA2587061C/en not_active Expired - Fee Related
-
2009
- 2009-03-25 US US12/410,540 patent/US20090263355A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN101056890A (zh) | 2007-10-17 |
| CN101056890B (zh) | 2012-05-09 |
| RU2404190C2 (ru) | 2010-11-20 |
| US20060120998A1 (en) | 2006-06-08 |
| KR101330626B1 (ko) | 2013-11-18 |
| WO2006053134A2 (en) | 2006-05-18 |
| CA2587061C (en) | 2011-08-16 |
| RU2007121515A (ru) | 2008-12-20 |
| ATE415421T1 (de) | 2008-12-15 |
| JP2008519769A (ja) | 2008-06-12 |
| KR20070084559A (ko) | 2007-08-24 |
| AU2005304486B2 (en) | 2011-08-11 |
| EP1809662A2 (en) | 2007-07-25 |
| BRPI0517697A (pt) | 2008-10-14 |
| PL1809662T3 (pl) | 2009-07-31 |
| MX2007004990A (es) | 2007-06-14 |
| US20090263355A1 (en) | 2009-10-22 |
| DE602005011321D1 (de) | 2009-01-08 |
| AU2005304486A1 (en) | 2006-05-18 |
| EP1809662B1 (en) | 2008-11-26 |
| US7595040B2 (en) | 2009-09-29 |
| PT1809662E (pt) | 2009-02-26 |
| CA2587061A1 (en) | 2006-05-18 |
| ES2318575T3 (es) | 2009-05-01 |
| WO2006053134A3 (en) | 2006-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Lin et al. | The role of Stat5a and Stat5b in signaling by IL-2 family cytokines | |
| Akira | Functional roles of STAT family proteins: lessons from knockout mice | |
| KR0184235B1 (ko) | 거핵구 형성 인자 | |
| May et al. | Phosphorylation of secreted forms of human β2-interferon/hepatocyte stimulating factor/interleukin-6 | |
| AU5164590A (en) | Use of il-7 in providing medications for stimulation of platelet production | |
| US20090263355A1 (en) | Deamidated interferon-beta | |
| ES2310413T3 (es) | Factores asociados con el factor de necrosis del tumor receptor de tipo 2 (tnf-r2). | |
| US20190307849A1 (en) | Methods of using interleukin-10 for treating diseases and disorders | |
| JP2010500024A (ja) | 強化された生物学的活性を有する組換えインターフェロン−β | |
| JP7707071B2 (ja) | コラーゲン７組成物を産生するための系および方法 | |
| EP0354989A1 (en) | Megakaryocytopoietin, preparation and use | |
| EP0679659B1 (en) | Cathepsin-l-specific inhibitor polypeptide | |
| EP0796276B1 (en) | Gradual modification, super-agonists and antagonists of signal-proteins and peptides | |
| JPWO2020032076A1 (ja) | 破骨細胞分化抑制剤 | |
| CN1055389A (zh) | 具有制瘤素m活性的新的蛋白质及其制备方法 | |
| CA2256368A1 (en) | An interleukin-5 antagonist | |
| JPH022391A (ja) | ヒトｍ―ｃｓｆ及びその製造法 | |
| STEBBING | PROTEINS AS THERAPEUTICS | |
| EP0576953A2 (en) | Production of human cathepsin and its use | |
| Liu | Regulation of A-alpha fibrinogen gene transcription in response to interleukin-6 | |
| JPH0259599A (ja) | 改良エリスロポイエチン組成物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080919 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20080919 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110412 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110614 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110621 |
|
| RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20110811 |
|
| RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20110811 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110812 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20110822 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20110811 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20111115 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20111215 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20141222 Year of fee payment: 3 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |